Share on LinkedInShare on LinkedIn

ARTICLE · 29 DECEMBER 2017

Federal Circuit Rules BPCIA Preempts State Law

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

On December 14, 2017, the U.S. Court of Appeals for the Federal Circuit again interpreted the Biologics Price Competition and Innovation Act ("BPCIA").

United StatesIntellectual Property

On December 14, 2017, the U.S. Court of Appeals for the Federal Circuit again interpreted the Biologics Price Competition and Innovation Act ("BPCIA"). In Amgen Inc. et al. v. Sandoz Inc., 15-cv-1499 (Fed. Cir. 2017), the Federal Circuit sided with Sandoz in ruling the BPCIA preempts state law remedies for noncompliance with 42 U.S.C. § 262(Ɩ)(2)(A) ("patent dance"). This case was decided on remand from the recent Supreme Court ruling in Sandoz Inc. v. Amgen Inc., 137 S. Ct. 1664 (2017), which held that federal injunctions are not available to compel "patent dance" disclosures. On remand, the Federal Circuit was asked to decide whether noncompliance with the patent dance requirements could violate California state law.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from